Tenofovir-emtricitabine (DrugBank: Emtricitabine, Tenofovir)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 25 | Progressive multifocal leukoencephalopathy | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00120367 (ClinicalTrials.gov) | April 2005 | 11/7/2005 | Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125) | Early Intensification of Combination Antiretroviral Therapy Including FUZEON® in the Treatment of Progressive Multifocal Leucoencephalopathy During HIV-1 Infection ANRS 125 Trial | Leukoencephalopathy, Progressive Multifocal;HIV Infections | Drug: Enfuvirtide;Drug: Tenofovir-Emtricitabine | French National Agency for Research on AIDS and Viral Hepatitis | Hoffmann-La Roche;Gilead Sciences | Completed | 18 Years | N/A | Both | 30 | Phase 2 | France |